纳米建筑学:纳米材料在抑制SARs-CoV-2/COVID-19疫苗接种策略中的作用

IF 3.3 Q3 NANOSCIENCE & NANOTECHNOLOGY Nanofabrication Pub Date : 2022-06-09 DOI:10.37819/nanofab.007.193
Iqra Zulfiqar, Abdul Wahab, M. U. Saeed, Nazim Hussain, M. Sabar, M. Bilal, Hafiz M.N. Iqbal
{"title":"纳米建筑学:纳米材料在抑制SARs-CoV-2/COVID-19疫苗接种策略中的作用","authors":"Iqra Zulfiqar, Abdul Wahab, M. U. Saeed, Nazim Hussain, M. Sabar, M. Bilal, Hafiz M.N. Iqbal","doi":"10.37819/nanofab.007.193","DOIUrl":null,"url":null,"abstract":"With the exponential rise in infections by CoV-2 and the scarcity of antiviral therapeutics, the development of an effective vaccine for the SARS CoV-2 is critical. The emerging pandemic has prompted the international science community to seek answers in therapeutic agents, including vaccines, to battle the SARS CoV-2. The various scientific literature on SARS CoV, to a lesser degree, MERS (Middle East Respiratory Syndrome), has mentored vaccine techniques for the unique Coronavirus. This disease, COVID-19, is triggered by SARS-CoV-2 virus that causes COVID-19 that needs vaccine protection. Vaccines producing significant amounts of virus-neutralizing antibodies with high affinity may be the only way to combat infection while avoiding negative consequences. There is a summary of numerous vaccine contenders in the review, including nucleotide, vector-based vaccines, & subunit, and attenuated & killed types. That has previously shown preventive effects against the MERS-CoV & SARS-CoV, while suggesting that these candidates may yield a safe and efficient vaccine for SARS-CoV-2. Vector-based vaccines, monoclonal antibodies, genetic vaccines, and protein subunit types for passive immunization are among the vaccination platforms currently being evaluated for the CoV-2 virus; each has its own set of benefits and drawbacks. The clinical safety and effectiveness evidence is the main challenging research task for this possible vaccine developed in the lab. The most challenging aspect of production is constructing and validating distribution platforms worthy of mass-producing the vaccine on a larger scale. Since target vaccine groups include high-risk people above the age of 60, including severe co-morbid diseases, the healthcare staff, and those engaged in vital industries, an effective COVID-19 vaccine would need a careful confirmation of effectiveness and detrimental reactivity. The study summarises efforts devoted to developing an efficient vaccine for the new Coronavirus that devastated the global economy, people's health, and even their lives.","PeriodicalId":51992,"journal":{"name":"Nanofabrication","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Nanoarchitectonics: role of nanomaterials in vaccination strategies for curbing SARs-CoV-2/COVID-19\",\"authors\":\"Iqra Zulfiqar, Abdul Wahab, M. U. Saeed, Nazim Hussain, M. Sabar, M. Bilal, Hafiz M.N. Iqbal\",\"doi\":\"10.37819/nanofab.007.193\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"With the exponential rise in infections by CoV-2 and the scarcity of antiviral therapeutics, the development of an effective vaccine for the SARS CoV-2 is critical. The emerging pandemic has prompted the international science community to seek answers in therapeutic agents, including vaccines, to battle the SARS CoV-2. The various scientific literature on SARS CoV, to a lesser degree, MERS (Middle East Respiratory Syndrome), has mentored vaccine techniques for the unique Coronavirus. This disease, COVID-19, is triggered by SARS-CoV-2 virus that causes COVID-19 that needs vaccine protection. Vaccines producing significant amounts of virus-neutralizing antibodies with high affinity may be the only way to combat infection while avoiding negative consequences. There is a summary of numerous vaccine contenders in the review, including nucleotide, vector-based vaccines, & subunit, and attenuated & killed types. That has previously shown preventive effects against the MERS-CoV & SARS-CoV, while suggesting that these candidates may yield a safe and efficient vaccine for SARS-CoV-2. Vector-based vaccines, monoclonal antibodies, genetic vaccines, and protein subunit types for passive immunization are among the vaccination platforms currently being evaluated for the CoV-2 virus; each has its own set of benefits and drawbacks. The clinical safety and effectiveness evidence is the main challenging research task for this possible vaccine developed in the lab. The most challenging aspect of production is constructing and validating distribution platforms worthy of mass-producing the vaccine on a larger scale. Since target vaccine groups include high-risk people above the age of 60, including severe co-morbid diseases, the healthcare staff, and those engaged in vital industries, an effective COVID-19 vaccine would need a careful confirmation of effectiveness and detrimental reactivity. The study summarises efforts devoted to developing an efficient vaccine for the new Coronavirus that devastated the global economy, people's health, and even their lives.\",\"PeriodicalId\":51992,\"journal\":{\"name\":\"Nanofabrication\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2022-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanofabrication\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37819/nanofab.007.193\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NANOSCIENCE & NANOTECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanofabrication","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37819/nanofab.007.193","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NANOSCIENCE & NANOTECHNOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

随着冠状病毒-2感染呈指数级上升,以及抗病毒治疗药物的稀缺,开发有效的SARS冠状病毒-2疫苗至关重要。新出现的大流行促使国际科学界寻求疫苗等治疗药物的答案,以对抗SARS CoV-2。关于SARS冠状病毒的各种科学文献,以及在较小程度上关于MERS(中东呼吸综合征)的文献,为这种独特的冠状病毒的疫苗技术提供了指导。这种疾病COVID-19是由SARS-CoV-2病毒引发的,该病毒会导致COVID-19,需要疫苗保护。产生大量高亲和力病毒中和抗体的疫苗可能是对抗感染同时避免负面后果的唯一途径。综述中总结了许多疫苗竞争者,包括核苷酸、载体疫苗、亚单位疫苗以及减毒和灭活疫苗。这之前已经显示出对MERS-CoV和SARS-CoV的预防作用,同时表明这些候选疫苗可能产生一种安全有效的SARS-CoV-2疫苗。基于载体的疫苗、单克隆抗体、遗传疫苗和被动免疫的蛋白质亚基类型是目前正在评估的CoV-2病毒疫苗接种平台;每种方法都有自己的优点和缺点。临床安全性和有效性证据是这种可能在实验室开发的疫苗的主要挑战性研究任务。生产中最具挑战性的方面是建立和验证值得大规模生产疫苗的分销平台。由于疫苗的目标人群包括60岁以上的高危人群,包括严重共病患者、医护人员和从事重要行业的人员,因此有效的COVID-19疫苗需要仔细确认其有效性和有害反应性。这项研究总结了为研制有效疫苗而付出的努力,这种新型冠状病毒摧毁了全球经济、人们的健康,甚至他们的生命。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Nanoarchitectonics: role of nanomaterials in vaccination strategies for curbing SARs-CoV-2/COVID-19
With the exponential rise in infections by CoV-2 and the scarcity of antiviral therapeutics, the development of an effective vaccine for the SARS CoV-2 is critical. The emerging pandemic has prompted the international science community to seek answers in therapeutic agents, including vaccines, to battle the SARS CoV-2. The various scientific literature on SARS CoV, to a lesser degree, MERS (Middle East Respiratory Syndrome), has mentored vaccine techniques for the unique Coronavirus. This disease, COVID-19, is triggered by SARS-CoV-2 virus that causes COVID-19 that needs vaccine protection. Vaccines producing significant amounts of virus-neutralizing antibodies with high affinity may be the only way to combat infection while avoiding negative consequences. There is a summary of numerous vaccine contenders in the review, including nucleotide, vector-based vaccines, & subunit, and attenuated & killed types. That has previously shown preventive effects against the MERS-CoV & SARS-CoV, while suggesting that these candidates may yield a safe and efficient vaccine for SARS-CoV-2. Vector-based vaccines, monoclonal antibodies, genetic vaccines, and protein subunit types for passive immunization are among the vaccination platforms currently being evaluated for the CoV-2 virus; each has its own set of benefits and drawbacks. The clinical safety and effectiveness evidence is the main challenging research task for this possible vaccine developed in the lab. The most challenging aspect of production is constructing and validating distribution platforms worthy of mass-producing the vaccine on a larger scale. Since target vaccine groups include high-risk people above the age of 60, including severe co-morbid diseases, the healthcare staff, and those engaged in vital industries, an effective COVID-19 vaccine would need a careful confirmation of effectiveness and detrimental reactivity. The study summarises efforts devoted to developing an efficient vaccine for the new Coronavirus that devastated the global economy, people's health, and even their lives.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nanofabrication
Nanofabrication NANOSCIENCE & NANOTECHNOLOGY-
自引率
10.30%
发文量
13
审稿时长
16 weeks
期刊最新文献
Recent updates on g-C3N4/ZnO-based binary and ternary heterojunction photocatalysts toward environmental remediation and energy conversion Lipid And Polymer Based Nano-Phytotherapeutics A Comprehensive Review of Nanocomposite PVDF as a Piezoelectric Material: Evaluating Manufacturing Methods, Energy Efficiency and Performance Nanocellulose-based Hydrogels: Preparation Strategies, Dye Adsorption and Factors Impacting Revisiting the advancement with painless microneedles for the diagnosis and treatment of dermal infections: A review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1